NeoPhore
Cambridge
About NeoPhore
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $44.7M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2024)
- Website: neophore.com
- Phone: +44 (0)1223 804250
Industries & Categories
Biotechnology, Simulation, Therapeutics, Translation Service
Social Profiles
Canonical: https://fsome.com/organization/neophore-87247 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.